

## Hydrogen Sulfide and Oxygen Sensing in the Cardiovascular System

Kenneth R. Olson<sup>1</sup> and Nathan L. Whitfield<sup>1,2</sup>

### Abstract

Vertebrate cardiorespiratory homeostasis is inextricably dependent upon specialized cells that provide feedback on oxygen status in the tissues, blood, and on occasion, environment. These “oxygen sensing” cells include chemoreceptors and oxygen-sensitive chromaffin cells that initiate cardiorespiratory reflexes, vascular smooth muscle cells that adjust perfusion to metabolism or ventilation, and other cells that condition themselves in response to episodic hypoxia. Identification of how these cells sense oxygen and transduce this into the appropriate physiological response has enormous clinical applicability, but despite intense research there is no consensus regarding the initial hypoxia-effector coupling mechanism. This review examines an alternative mechanism of oxygen sensing using oxidation of endogenously produced hydrogen sulfide (H<sub>2</sub>S) as the O<sub>2</sub>-sensitive couple. Support for this hypothesis includes the similarity of effects of hypoxia and H<sub>2</sub>S on a variety of tissues, augmentation of hypoxic responses by precursors of H<sub>2</sub>S production and their inhibition by inhibitors of H<sub>2</sub>S synthesis, and the rapid consumption of H<sub>2</sub>S by O<sub>2</sub> in the range of intracellular/mitochondrial Po<sub>2</sub>. These studies also indicate that, under normoxic conditions, it is doubtful that free H<sub>2</sub>S has longer than a transient existence in tissue or extracellular fluid. *Antioxid. Redox Signal.* 12, 1219–1234.

### Introduction

IN COINING THE TERM “GASOTRANSMITTER,” Rui Wang specified that these signaling molecules must be: (a) small molecules of gas, (b) freely membrane permeable, (c) endogenously and enzymatically generated and this must be regulated, (d) have defined functions at physiological concentrations, and (e) have specific molecular targets (68). With the exception of the first two, these are the same characteristics of neurotransmitters. One could add an additional criterion for gasotransmitters, or signaling systems in general: the optimal signaling mechanism should possess characteristics that either render it uniquely sensitive to the regulated parameter, or make it particularly efficacious in driving the effector response. Ideally it would have both. This review examines one gasotransmitter, hydrogen sulfide (H<sub>2</sub>S), and its potential role in acute oxygen (O<sub>2</sub>) sensing. Long-term (chronic) effectors of hypoxic responses that regulate genetic responses, such as the hypoxia inducible factor (HIF) transcription factor family, sustain and augment the initial responses but are not considered here.

In this review we will present evidence to support the hypothesis that O<sub>2</sub>-driven H<sub>2</sub>S metabolism is a physiologically significant O<sub>2</sub> sensor that responds to acute hypoxia in a

variety of biological systems. In order to support this model, it must be demonstrated that H<sub>2</sub>S can be produced and metabolized by O<sub>2</sub> sensing cells, H<sub>2</sub>S is consumed by the cells in the presence of O<sub>2</sub>, and H<sub>2</sub>S initiates the appropriate effector response.

### Variations of Hypoxia

While hyperoxia has deleterious consequences of its own, the most serious and pervasive threat to eukaryotic cells is hypoxia. This can be of either external or internal origin.

When terrestrial animals ascend to higher altitudes, ambient partial pressure of oxygen (Po<sub>2</sub>) falls due to the decrease in barometric pressure according to the relationship: Po<sub>2</sub> = fo<sub>2</sub> · Pb; where fo<sub>2</sub> is the altitude-independent mole fraction of oxygen in air (0.21) and Pb is the altitude-dependent barometric pressure. At 3,000 meters Pb and therefore Po<sub>2</sub> is 30% lower than at sea level. For climbers at the summit of Mount Everest (8,848 meters) the ambient (and arterial) Po<sub>2</sub> is ~43 mmHg, and for all practical purpose the lower limit for human survival (39). Burrowing animals may have little convective delivery of fresh air into their burrows and likewise experience very low (40–50 mmHg) Po<sub>2</sub>s (55). Air-breathing animals that forage for food underwater (*i.e.*,

<sup>1</sup>Indiana University School of Medicine, South Bend Center, South Bend, Indiana.

<sup>2</sup>Department of Biological Sciences, University of Notre Dame, Notre Dame, Indiana.

whales, porpoises, seals, otters, penguins, and some ducks), may remain underwater for extended periods (up to 2 h) and since they are unable to obtain oxygen from the environment are subjected to an acute and abrupt environmental anoxia. Even the mammalian fetus experiences a form of external hypoxia relative to an adult as the arterial  $\text{Po}_2$  is usually no more than 40 mmHg (69).

Aquatic hypoxia is even more problematic. Compared to air, water has a lower capacity for  $\text{O}_2$  (1/30), diffusion through water is slower (Krogh's diffusion coefficients 1/200,000), and  $\text{O}_2$  solubility decreases by ~20% for every 10°C increase in temperature and another 20% in seawater compared to freshwater. Water's high viscosity (60 times that of air) increases ventilatory work and can decrease convective delivery of  $\text{O}_2$  from  $\text{O}_2$ -rich surface water. Furthermore, ambient hypoxia occurs in aquatic environments seasonally, diurnally, or episodically, it is a common feature of both freshwater and saltwater environments, and it is often associated with increased  $[\text{H}_2\text{S}]$  (3).

Hypoxia of internal origin can be either global or regional. Global internal hypoxia can be produced by a decrease in the ventilation/perfusion ratio in the respiratory organs or impaired diffusion across the gas exchange surface. The former is most often the result of impaired ventilation [*i.e.*, a variety of hypoventilation syndromes (obesity, neuromuscular, skeletal, obstructive sleep apnea, chronic obstructive lung disease; COPD), and the latter from pulmonary edema (60)]. Often these clinical scenarios have multiple effects. Insufficient  $\text{O}_2$  uptake produces hypoxemia (low blood  $\text{O}_2$  content). Tissue hypoxia can result from delivery of hypoxemic blood (hypoxemic hypoxia) or insufficient blood flow relative to metabolism (ischemia or ischemic hypoxia).

### **$\text{O}_2$ Reporting, $\text{O}_2$ Responding, and $\text{O}_2$ Sensitive Cells**

Cells can be divided into three main categories, depending on their response to changes in either oxygen content or  $\text{Po}_2$ : oxygen reporters, oxygen responders, or oxygen-sensitive cells.  $\text{O}_2$  reporters monitor external or internal oxygen status and typically initiate distant cardioventilatory effector responses.  $\text{O}_2$  responders monitor local or regional oxygen status and initiate effector responses in the same general area.  $\text{O}_2$  sensitive cells respond metabolically to changes in oxygenation but typically they do not affect other cells.

#### *$\text{O}_2$ reporters*

**Monitors of external hypoxia.** Clusters of  $\text{O}_2$ -sensitive cells form neuroepithelial bodies (NEBs) that line the airways of mammalian lungs (26). NEBs are most prominent in neonatal lungs, especially near airway bifurcations. They are believed to monitor airway  $\text{Po}_2$  and help initiate breathing and optimize ventilation/perfusion matching. NEBs act through both central reflexes and local (paracrine) stimulation of adjacent pulmonary vasculature (26). NEB cells are more responsive to airway hypoxia than hypoxemia. The role of NEB in adult animals is unclear and it remains to be identified if they function as a general monitor of environmental  $\text{Po}_2$  in air-breathing vertebrates.

Aquatic vertebrates, such as fish and most larval and a few adult amphibians (*e.g.*, tadpoles, frogs, salamanders, and caecilians), are often subjected to environmental hypoxia and possess well-developed external  $\text{O}_2$ -reporting neuroepithelial

(NECs) cells. NECs are scattered over the gill surface, and they are especially prevalent distally on the leading (inhalant) edge of the gill filament. In hypoxia-sensitive fish such as trout, they initiate a reflex bradycardia and increase ventilatory rate and amplitude when water  $\text{Po}_2$  falls to 75–100 mmHg (38). In some fish (*e.g.*, trout), these NECs are predominantly on the first gill arch, the homolog of the mammalian carotid body; in others (bowfin, catfish) they are more evenly distributed over the gills and even orobranchial cavity (38).

**Monitors of hypoxemia.** Carotid bodies in mammals and other tetrapods are small paired organs located at the bifurcation of the internal and external carotid arteries and ideally positioned to monitor  $\text{O}_2$  delivery to the brain. Because their blood flow and  $\text{O}_2$  consumption per tissue weight is the highest of any organ, they are reporters of blood  $\text{Po}_2$  rather than  $\text{O}_2$  content. Carotid bodies are the primary, if not only, sensor of acute and chronic arterial hypoxemia in the adult mammal (38). Type I glomus cells, similar to the NEC of lower vertebrates, are the primary chemosensory cell. The  $\text{Po}_2$  threshold for activation of isolated type I cells from the rabbit is ~40 mmHg and half-maximal activation of many of these cells occurs ~10 mmHg or less (5). Given their high metabolic rate, it is quite likely that the intracellular  $\text{Po}_2$  at which the glomus cells are activated is considerably lower. Although many neurotransmitters have been identified in the carotid body, the main neurotransmitters appear to be acetylcholine and ATP (54). Discharge from the carotid bodies is integrated into complex cardiovascular reflexes. Hypoxemia initiates an increase in ventilation and peripheral vasoconstriction when breathing is unimpaired, while it produces a reflex bradycardia and peripheral vasoconstriction if breathing is not possible. Although fish lack carotid bodies, vascularly oriented NECs in the gills are homologous monitors of arterial  $\text{Po}_2$ . Unlike their mammalian counterparts, they appear more sensitive to blood oxygen content than blood  $\text{Po}_2$  and they secrete serotonin in response to hypoxemia which also stimulates ventilation (38).

$\text{O}_2$ -sensitive chromaffin cells are present in the adrenal medulla of fetal and newborn, but not adult, mammals and in the heart and vasculature (mainly systemic veins) of adults from the more primitive vertebrates (41). Hypoxemia stimulates the mammalian adrenomedullary chromaffin cells to release catecholamines into the bloodstream where they have stimulatory cardiorespiratory effects. Their location suggests that they provide information on the balance between  $\text{O}_2$  delivery and tissue utilization although the low  $\text{Po}_2$  threshold for secretion, <5 mmHg, suggests that they are more active during severe hypoxia. In fish, hypoxemia stimulates catecholamine secretion which initiates cardiorespiratory responses and increases  $\text{O}_2$  transport by red blood cells.

#### *$\text{O}_2$ responders*

Blood vessels are perhaps the best example of local  $\text{O}_2$  responders and this has been extensively studied in mammals where hypoxia contracts pulmonary vessels, relaxes systemic vessels, and in the fetus relaxes the ductus arteriosus. Hypoxic pulmonary vasoconstriction (HPV) decreases perfusion of poorly ventilated regions of the lung, and thus decreases the potential for partial unsaturation of pulmonary venous (systemic arterial) blood. Hypoxic systemic vasodilation (HSD)

increases tissue perfusion, thereby increasing O<sub>2</sub> delivery. Both HPV and HSD are intrinsic responses of pulmonary and systemic vascular smooth muscle cells (36). Although HPV is believed to be a unique attribute of the pulmonary circulation, this is not the case in nonmammalian vertebrates as hypoxia also constricts many systemic conductance (>500  $\mu$ m dia) vessels in a range of vertebrates from hagfish and lamprey to birds (44). Furthermore, we have recently shown that hypoxia also dilates resistance (<400  $\mu$ m dia) pulmonary arterioles in diving mammals (48) and birds (Olson and Madden unpublished). The effects of hypoxia on respiratory and systemic vessels from a wide range of vertebrates are summarized in Table 1 and several examples shown in Fig. 1.

### O<sub>2</sub> sensitive cells

Essentially all cells are affected by hypoxia and the most pervasive responses to cellular hypoxia is hypometabolism and alterations in gene expression (12, 55). While metabolic depression has been induced by combined hypoxia and/or H<sub>2</sub>S in small mammals, it is beyond the scope of this review. Cells from many tissues have also shown the ability to be 'conditioned' against injury resulting from reperfusion after prolonged ischemia by being pre-treated with several brief hypoxic episodes. These mechanisms will be considered in subsequent sections.

## O<sub>2</sub> Sensing Mechanisms

### O<sub>2</sub> reporting and O<sub>2</sub> responding cells

The search for O<sub>2</sub> sensors has heavily emphasized mammalian blood vessels and chemoreceptors. Initial studies


suggested that depolarization due to closure of O<sub>2</sub>-sensitive, voltage-gated potassium (Kv) channels in pulmonary arterial smooth muscle cells, or hyperpolarization after opening ATP-dependent potassium channels (KATP) in systemic vascular smooth muscle, would produce the appropriate change in intracellular calcium leading to vasoconstriction or dilation, respectively. Kv channels have been identified in most, if not all, O<sub>2</sub>-sensing tissues including pulmonary arteries, carotid and neuroepithelial bodies, adrenal chromaffin cells (33, 41), and fish gill neuroepithelial cells (24). K<sup>+</sup>ATP channels are also common in systemic vessels and these, along with the possible loss of the O<sub>2</sub>-sensitive K<sub>v</sub>1.5 and K<sub>v</sub>2.1 channels, may account for HSD (65). It is now evident, however, that while O<sub>2</sub>-sensitive K<sup>+</sup> channels may contribute to, or modulate, the hypoxic response, other factors "upstream" from these or other K<sup>+</sup> channels most likely couple hypoxia to K<sup>+</sup> channels (72).

Most studies seem to agree that HPV is ultimately achieved through an increase in intracellular Ca<sup>2+</sup>, via voltage-gated, TRP channels, or store-operated channels and/or intracellular ryanodine-sensitive stores, and by Ca<sup>2+</sup> sensitization, via Rho kinase or other mechanisms (69). A number of intracellular signaling systems [e.g., K<sup>+</sup> channels, protein kinase C (PKC)], are also activated downstream, but the initiating O<sub>2</sub> sensor/transducer that couples O<sub>2</sub> concentration or availability to the physiological response is unknown. Because mitochondria are the primary cellular O<sub>2</sub> consumers, it is reasonable to expect the sensing mechanism to reside in these organelles or to be closely associated with them, and this is the current consensus. How this is accomplished, however, remains hotly debated. There are currently three prominent theories for the "O<sub>2</sub> sensor", the redox theory, the ROS theory, and the AMP-activated kinase theory. The "redox theory" proposes that in normoxic conditions the proximal mitochondrial electron transport chain generates a diffusible reactive oxygen species (ROS), such as H<sub>2</sub>O<sub>2</sub>, that keeps Kv channels open and the resulting hyperpolarization ensures that the calcium channels remain closed, thereby maintaining relaxation. During hypoxia, mitochondrial ROS production falls and the cytosol becomes more reduced. Under these conditions, the Kv channels now close, which depolarizes the cell and ultimately produces HPV (72). The ROS hypothesis is based on an increase in ROS during hypoxia which then may inhibit Kv channels, open TRP channels via activation of phospholipase C, affect Ca<sup>2+</sup> release by stimulating ryanodine channels in the sarcoplasmic reticulum, and increase Ca<sup>2+</sup> sensitization (70). The redox and ROS theories depend on whether hypoxia decreases or increases ROS and this has not been resolved. This conundrum may be methodological, nevertheless, it has generated an interesting dialog (70). The AMP kinase hypothesis links energy state to HPV and is independent of redox state or ROS. It is based on the increase in adenosine monophosphate (AMP)/ATP ratio that results from increased reliance on ATP synthesis from two ADP (forming 1 AMP and 1 ATP) when mitochondrial oxidative phosphorylation is compromised. The increased AMP/ATP ratio activates AMP kinase and the resulting downstream increase in cyclic adenosine diphosphate-ribose (cADPR) stimulates Ca<sup>2+</sup> release from the ryanodine sensitive Ca<sup>2+</sup> stores in the sarcoplasmic reticulum (11). The O<sub>2</sub>-sensor has also been proposed to be metabolic products derived from O<sub>2</sub>-dependent reactions catalyzed by enzymes such as NADPH oxidases, heme oxygenases, cytochrome

TABLE 1. PHYLOGENETIC COMPARISON OF HYPOXIA AND H<sub>2</sub>S VASOACTIVITY

	Systemic		Pulmonary		Reference
	Hypoxia	H <sub>2</sub> S	Hypoxia	H <sub>2</sub> S	
Resistance					
Cow			+	+	a
Seal			-	-	a
Penguin			-	-	b
Conductance					
Cow	-	-	(-)+	(-)+	c
Seal	- or +	- or +	- or +	- or +	c
Rat	-	-	+ - +	+ - +	c
Duck	+	+	- +	- +	c
Alligator	+	+	+ - +	+ - +	c
Toad	+	+	+	+	c
Trout	- + -	- + -	+	+	c
Shark	-	-			c
Lamprey	+	+	(+) -	(+) -	c
Hagfish	+	+	(+) -	(+) -	d,e
Perfused					
Rat (lung)			+	+	f
Trout (gill)			+	+	g

+, contraction; -, relaxation; multiple symbols (+ - +) multiphasic response; symbols in parentheses are minor responses; symbols separated by 'or' indicate different responses in different vessels but same response to hypoxia and H<sub>2</sub>S. Citations: a, 48; b, Olson and Madden, unpublished observations; c, 44; d, 47; e, 45; f, 35; g, Skovgaard and Olson, unpublished observations.



**FIG. 1. Similarity of hypoxia and H<sub>2</sub>S effects in blood vessels.** Hypoxia (100% N<sub>2</sub>) and H<sub>2</sub>S (300 μmol l<sup>-1</sup>; as total sulfide, H<sub>2</sub>S + HS<sup>-</sup>) produce identical responses in conductance (>500 μm diameter) vessels from (A) rat thoracic aorta, (B) rat pulmonary artery, (C) lamprey dorsal aorta, and (D) bovine pulmonary artery. Vessels pre-contracted with 10<sup>-6</sup> mol l<sup>-1</sup> norepinephrine (NE) or U-46619 (thromboxane A<sub>2</sub> mimetic; 10<sup>-7</sup> mol l<sup>-1</sup>); air, aeration with room air; w, wash; 1, 2, 3, tri-phasic response. Horizontal time bar in A–D = 10 min, vertical tension scale = 0.5 g. (E) hypoxia (P<sub>O<sub>2</sub></sub> ~50 mmHg) and H<sub>2</sub>S (3 × 10<sup>-4</sup> M) produce identical contractions of cow resistance (<500 μm diameter) pulmonary arteries while both stimuli relax sea lion resistance pulmonary arteries. Mean ± SE; N (animals, vessels) = cow (9, 9), sea lion (3, 5). A–D, adapted from ref. 44, with permission; E, adapted from ref. 48, with permission.

P-450 monooxygenases, and enzymes that degrade hypoxia-inducible factor-1 (69).

Hypoxic vasodilation may or may not be associated with a decrease in intracellular calcium, and has been proposed to be initiated by intracellular acidosis, redox control of cytosolic NADPH, and direct modulation of internal Ca<sup>2+</sup> stores and Rho-kinase (65). Hypoxia dilates the ductus arteriosus *in utero*, whereas the normoxic vasoconstriction occurring after birth has been attributed to inhibition of the same Kv channels and Ca<sup>2+</sup> entry through L-type channels as HPV, and also to an increase in Rho kinase (72).

In carotid body type I cells, hypoxia has been reported to activate NADPH oxidase and increase reactive oxygen species (ROS), activate AMP-activated protein kinase, inhibit mitochondrial metabolism, or stimulate heme oxygenase-2 (HO-2) production of carbon monoxide (54). In airway NEB, hypoxia has been proposed to inactivate NADPH oxidase thereby decreasing ROS (26, 41), and in adrenal chromaffin cells a mitochondrial mechanism decreases ROS (41).

Each of the above vascular and chemoreceptor O<sub>2</sub> sensing mechanisms has its proponents and opponents and arguments for and against these mechanisms have been recapitulated in numerous reviews (cf.; 33, 39, 60, 69, 70, 72). The most consistent observation is a lack of consensus.

#### O<sub>2</sub> sensitive cells—

##### ischemic reperfusion injury and conditioning

Reperfusion injury (RI) is a progression of pathological events such as microvascular dysfunction, tissue necrosis, and apoptosis that follow restoration of blood flow to ischemic tissue. In the myocardium, where RI is most extensively studied, it may be expressed as myocardial stunning (a reversible mechanical dysfunction), no-flow phenomena (an inability to restore perfusion), arrhythmias, or cell death. While RI is detrimental, there is considerable evidence that many cells respond to brief episodic exposures to hypoxia by initiating a variety of mechanisms that protect against RI. This ischemic preconditioning (IPreC) is produced by several transient ischemic periods prior to the prolonged ischemia and can protect the heart from RI for 1–2 h (first window) and this is followed 24 h later by a second window of protection that lasts an additional 48–72 h. The early phase appears to be associated with modification of existing proteins, whereas the latter requires additional protein synthesis. Preconditioning is obviously of limited clinical value and it was not until the discovery that transient ischemic periods after the prolonged ischemia (ischemic postconditioning; IPostC) also conveyed protection that the therapeutic benefit of conditioning was

realized (16). The conditioning effect is also portable, remote ischemic preconditioning (RIPrC) is produced by transient ischemia of one organ (often a limb) and it conveys a protective effect to a remote organ or tissue (63). Effects of ischemic conditioning have now been demonstrated in essentially all major organs including the heart, brain, liver, kidney, and skeletal muscle.

A number of factors have been proposed to mediate RI including oxidative stress, an abrupt increase in intracellular calcium, rapid restoration of pH following washout of lactic acid, and inflammatory responses (66). Any of these can open the mitochondrial permeability transition pore (MPTP) and initiate a cascade of cell death.

It is now clear that events during the early period of reperfusion are key to RI and that the benefits of both IPrC and IPoC address these events (16, 66). Activation of adenosine, bradykinin, and opioid G-protein coupled receptors appears to initiate cardioprotection. Adenosine directly activates PKC via phospholipases, whereas the others act through complex mechanisms that include phosphatidylinositol 3-kinase, Akt, nitric oxide synthase, guanylyl cyclase, PKG, opening of mitochondrial K<sub>ATP</sub> channels, and redox activation of PKC. This involves the reperfusion injury survival kinases (RISK), P13 kinase, and MEK-ERK 1/2 pathways. While various isoforms of protein kinase C (PKC $_{\alpha}$ , PKC $_{\beta}$ , PKC $_{\delta}$ ) are involved in IPrC and IPoC, they act downstream from ROS. The mitochondrial permeability transition pore may be the pivotal point of cell survival and Akt and ERK survival kinases are key in inhibiting pore formation until the ischemic injury is repaired (16, 66). Remote conditioning appears to be mediated by similar mechanisms but it is not known if the initial signal is neural or humoral. While ROS are generated upon reperfusion of the ischemic tissue, and the mitochondria appear to be the pivotal point through which RI and conditioning effects act, the molecular couple from hypoxia to the downstream effectors is unknown.

## H<sub>2</sub>S as an O<sub>2</sub> Sensor

### *Is there a universal O<sub>2</sub> sensor?*

There is some opinion that the O<sub>2</sub> sensor should be a macromolecule, most likely a protein that would be drawn from a pool of proteins naturally undergoing oxido-reductive transitions (53), or an oxygen consuming or binding protein/organelle (60). Clearly there are a variety of proteins that are involved in O<sub>2</sub> sensing/signal transduction, but does this array of candidates suggest that O<sub>2</sub> sensing mechanisms evolved numerous times and now constitutes a highly redundant system, or that different sensing mechanisms may be uniquely adapted to specific tissues (69)? Alternatively, it may reflect the fact that these mechanisms are downstream effectors/modulators of a more fundamental and universal process.

### *The basic model of H<sub>2</sub>S-mediated O<sub>2</sub> sensing*

The proposed model of H<sub>2</sub>S-mediated O<sub>2</sub> sensing (Fig. 2) does not require a complex or sophisticated O<sub>2</sub> "receptor". Instead, the signaling element is simply the balance between H<sub>2</sub>S production and its destruction by available O<sub>2</sub>. In other words, when intracellular O<sub>2</sub> falls, the rate of H<sub>2</sub>S metabolism can no longer keep pace with production, intracellular

H<sub>2</sub>S concentration increases, and H<sub>2</sub>S now activates the cell via a variety of cell-specific pathways. This model of H<sub>2</sub>S-mediated O<sub>2</sub> sensing presumes that; (a) the effects of H<sub>2</sub>S on O<sub>2</sub>-sensitive tissues are the same as that of hypoxia and that H<sub>2</sub>S activates the same intracellular processes, (b) H<sub>2</sub>S is constitutively produced in or near the O<sub>2</sub> sensing cell, (c) H<sub>2</sub>S is readily metabolized by these same tissues in an O<sub>2</sub>-dependent manner. The following sections provide support for this model.

### *General aspects of H<sub>2</sub>S signaling*

As shown in this issue, and in numerous recent reviews, H<sub>2</sub>S has an almost ubiquitous presence in tissues. Physio-pharmacological effects of H<sub>2</sub>S have been demonstrated in neurological, cardiovascular, gastrointestinal, genitourinary, endocrine, and immune systems and it has been proposed to be both pro- and anti-inflammatory (62, 68). H<sub>2</sub>S has also been reported to induce suspended animation in small mammals and be of potential benefit in organ survival (2).


H<sub>2</sub>S is synthesized in many, if not all, tissues (8). H<sub>2</sub>S can be produced directly from cysteine desulfuration via the cytosolic pyridoxyl 5'phosphate-dependent enzymes, cystathionine  $\lambda$ -lyase (CSE, aka CGL; EC 4.4.1.1), cystathionine  $\beta$ -synthase (CBS; EC 4.2.1.22), or after cysteine transamination to 3-mercaptopyruvate (often with  $\alpha$ -ketoglutarate,  $\alpha$ -KG, as the amine acceptor) and desulfuration by the 3-mercaptopyruvate sulfurtransferase (3-MST; EC 2.8.1.2; refs. 34 and 58). There are numerous other potential metabolic pathways for H<sub>2</sub>S generation that have been described for invertebrates (25) but they have not been systematically evaluated in mammalian tissues. It is also possible that H<sub>2</sub>S may be liberated directly from sulfane sulfur or acid-labile sulfur by reducing or acidic conditions, respectively (58). CBS and CSE appear to be sensitive to Po<sub>2</sub> or intracellular redox state (34) and this may directly contribute O<sub>2</sub> sensitivity or may provide a long-term mechanism to bias the rate of constitutive H<sub>2</sub>S production. Commonly used inhibitors of CSE include propargyl glycine (PPG) and  $\beta$ -cyanoalanine (BCA). Aminoxyacetate (AOA) is commonly used to inhibit CBS and hydroxylamine (HA) to inhibit both enzymes. Unfortunately, none of these inhibitors are specific for H<sub>2</sub>S metabolism and often they are poorly absorbed by tissues (62).

H<sub>2</sub>S oxidation has been demonstrated in vertebrate mitochondria. Sulfide-quinone oxidoreductase (SQR), a C-S-transhydrogenase in the glutathione reductase family, catalyzes electron transfer from H<sub>2</sub>S to carbon centers in NAD(P)H-NAD(P)<sup>+</sup>, and has been demonstrated in bacterial, invertebrate, and mammalian cells (17). SQR is a mitochondrial enzyme in eukaryotic cells and consumes one mole of O<sub>2</sub> for every mole of H<sub>2</sub>S oxidized (17). Thus, O<sub>2</sub> consumption is obligatory during H<sub>2</sub>S metabolism.

## H<sub>2</sub>S as a Vascular O<sub>2</sub> Sensor

### *Vascular effects of H<sub>2</sub>S are similar to hypoxic responses*

**Mammalian systemic vessels.** H<sub>2</sub>S has long been known in mammals to dilate systemic vessels, decrease vascular resistance, and decrease arterial blood pressure (1, 14, 27, 28, 29, 31, 71, 76). The effects of H<sub>2</sub>S on systemic vessels are identical to the effects of hypoxia (Fig. 1, Table 1).



**FIG. 2. Proposed mechanism using  $H_2S$  metabolism as an  $O_2$  sensor (A, B) and suggested pathway for mitochondrial sulfide oxidation (C).**  $H_2S$  is constitutively produced from cysteine (CYS) metabolism in the cytosol. During normoxia (A)  $H_2S$  is continuously oxidized to thiosulfate in the mitochondria, thereby maintaining low intracellular  $[H_2S]$ . A fall in oxygen availability (B) decreases mitochondrial  $H_2S$  oxidation resulting in an increase in biologically active  $[H_2S]$  and initiation of hypoxic responses. The enzymes generating  $H_2S$  from cysteine, cystathionine  $\beta$ -synthase (CBS) and cystathionine  $\gamma$ -lyase (CSE), also have the potential of  $O_2$  sensitivity, thereby enabling either short-term regulation of  $[H_2S]$  or placing a long-term bias on the rate of  $H_2S$  metabolism. (C) A membrane-bound sulfide:quinone oxidoreductase (SQR) oxidizes sulfide to the level of elemental sulfur, simultaneously reducing a cysteine disulfide such that a persulfide group is formed at one of the cysteines (SQR-SSH). The electrons are fed into the respiratory chain via the quinone pool (Q<sub>ox</sub>/Q<sub>red</sub>), and finally transferred to oxygen by cytochrome oxidase (complex IV). A sulfur dioxygenase in the mitochondrial matrix oxidizes persulfides to sulfite ( $H_2SO_3$ ), consuming molecular oxygen and water. The final reaction is catalyzed by a sulfur transferase, which produces thiosulfate ( $H_2S_2O_3$ ) by transferring a second persulfide from the SQR to sulfite. A, B, adapted from ref. 42, with permission; C 17, with permission.

$H_2S$  relaxes precontracted systemic vessels partly through activation of  $K_{ATP}$  channels and to a lesser extent through  $Ca^{2+}$ -dependent  $K^+$  ( $K_{Ca}$ ) channels and  $H_2S$ -mediated charybdotoxin/apamin-sensitive  $K^+$  channels in the endothelium (27, 76, 77) and partly through a reduction in intracellular pH (31).  $H_2S$ -induced relaxation appears to depend on extracellular  $Ca^{2+}$  (76). Relaxation of rat aorta by exogenous  $H_2S$  does not depend on vascular prostaglandin synthesis, protein kinase C, or cAMP, nor does it involve superoxide or  $H_2O_2$  production (27, 28). The relationship between  $H_2S$  and NO is far from resolved.  $H_2S$  relaxations have been reported to be independent of NO synthesis or cGMP activation (27, 28, 76) and Whiteman *et al.* (73) showed that  $H_2S$  combined with NO to produce a nitrosothiol that does not stimulate cGMP production in cultured RAW264.7 cells. NO production has been shown to be directly inhibited by  $H_2S$  (29) or indirectly stimulated by it through activating nuclear factor (NF- $\kappa$ B) which activated the extracellular regulated kinase 1/2 (ERK1/2) which in turn activated iNOS (23).

Reports of  $H_2S$ -mediated vasoconstrictory responses in mammalian systemic vessels are rare, and many of these

show an endothelium-dependent effect that has been attributed to  $H_2S$  inactivation of NO. Low concentrations of  $H_2S$  ( $<200 \mu M$ ) produce endothelium-dependent contraction of human internal mammary arteries and rat and mouse aortas (1, 29, 71) and low-dose  $H_2S$  infusion increases blood pressure in the rat (1). These contractions have been proposed to result from  $H_2S$  inactivation of endothelial NO via production of an inactive nitrosothiol (1, 71), whereas Kubu *et al.* (29) showed that  $H_2S$  directly inhibited NO production. Conversely,  $H_2S$  and NO appear to combine to produce a vasoactive molecule that relaxes trout arteries (Dombkowski and Olson, unpublished). Other studies suggest that  $H_2S$  may have direct, albeit modest, constrictory effects on systemic vascular smooth muscle. Lim (32) observed  $1 \mu M$   $H_2S$  contractions of rat aortas that were partially independent of both the endothelium and  $K_{ATP}$  channels and due in part to down regulation of cAMP. This leaves the option open for a direct constrictory effect of  $H_2S$ .

**Mammalian pulmonary vessels.**  $H_2S$  produces the same effect in mammalian pulmonary arteries as hypoxia, that is,

contraction of bovine conductance (>500  $\mu$ m diameter) pulmonary arteries (CPA) and triphasic contraction-relaxation-contraction of rat CPA (Fig. 1B and D, Table 1). The fact that H<sub>2</sub>S was the only molecule found to mimic the signature triphasic response in rat CPA provided the first clue that H<sub>2</sub>S may be involved in the hypoxic response (44). Perhaps the most convincing argument, however, comes from a recent examination of resistance (<500  $\mu$ m diameter) pulmonary arteries (RPA) in the cow and sea lion where both H<sub>2</sub>S and hypoxia contracted cow RPA, yet relaxed sea lion RPA (Fig. 1E; 48). This was not only the first demonstration of hypoxic relaxation in a mammalian RPA, but it provided additional evidence of the uniformity of H<sub>2</sub>S and hypoxic responses in the vasculature. H<sub>2</sub>S and hypoxia also increase vascular resistance in the perfused rat lung (35). In addition to these vasoactive responses, hypoxia and H<sub>2</sub>S have other common effects. Both produce a similar depolarization of smooth muscle cells from bovine pulmonary arteries (44) and both cause phosphorylation of myosin light chain in cat pulmonary arteries (36; and unpublished).

**Nonmammalian vessels.** We have compared H<sub>2</sub>S and hypoxic responses in respiratory and systemic conductance vessels from at least one species of each class of vertebrates (eight nonmammalian species total) and found that while both H<sub>2</sub>S and hypoxia tend to contract respiratory vessels, their effects on systemic blood vessels are variable, some vessels contract, some relax, and in some the response is bi- or multiphasic; however, in every vessel the effect of H<sub>2</sub>S and hypoxia are the same (Fig. 1C, Table 1) (44, 45, 47). H<sub>2</sub>S and hypoxia also increase vascular resistance in the perfused trout gill (42; Skovgaard and Olson, unpublished observations). These disparate responses are not due to major differences in the contractile machinery as all vessels are similarly contracted by a variety of agonists such as elevated extracellular K<sup>+</sup> and thromboxane A<sub>2</sub> agonists and relaxed by NO donors or natriuretic peptides.

It is interesting to note that in support of the redox theory for hypoxic pulmonary vasoconstriction and ductus arteriosus vasodilation, Weir *et al.* (21) observe that only redox changes mimic oxygen by constricting pulmonary arteries and dilating the ductus arteriosus whereas other stimuli such as elevated extracellular K<sup>+</sup> contract both. H<sub>2</sub>S appears to do the same in a considerable variety of vessels. One could argue that H<sub>2</sub>S also reduces the cytosolic environment, however, antioxidants tend to suppress HPV, suggesting that the mechanism of H<sub>2</sub>S vasoconstriction is not as a reductant.

#### *H<sub>2</sub>S metabolism in the vasculature*

CBS and CSE are thought to be differentially expressed in tissues, CSE is prevalent in systemic and pulmonary arteries and the heart, but not found in brain, whereas only CBS is found in the brain (62). Recent studies have shown that 3-MST, not CBS, appears to be the major pathway for H<sub>2</sub>S synthesis in the brain (58) but, other than our work (below) 3-MST has not been examined in the vasculature. In contrast to mammals, we have found both CSE and CBS mRNA in trout arteries, veins, heart, brain, liver, gut, gill, and skeletal muscle (46), suggesting a ubiquitous expression of these enzymes in fish. We have also found CBS mRNA and CBS immunoreac-

tivity in the endothelium of sea lion and bovine pulmonary arteries (48).

#### *Similarities between H<sub>2</sub>S stimulation and activation of O<sub>2</sub>-sensitive chemoreceptors*

The involvement of H<sub>2</sub>S in O<sub>2</sub>-sensitive chemoreceptors in the carotid body is beginning to receive attention. In a preliminary study, Rong *et al.* (56) recorded afferent nerve activity from an isolated mouse carotid sinus nerve preparation and found that H<sub>2</sub>S increased chemoreceptor afferent discharge in a concentration-dependent fashion through attenuation of large conductance, calcium-sensitive potassium (BKCa) channels. H<sub>2</sub>S activity appeared specific for the glomus cells. They also found that O<sub>2</sub> sensitivity was enhanced in the presence of H<sub>2</sub>S, whereas chemoreceptor response to hypoxia was abolished by the CBS inhibitor, AOA, but not by CSE inhibitors, PPG or BCA. Recently, Telezhkin *et al.* (64) identified CSE in glomus cells from the rat carotid body and found that H<sub>2</sub>S inhibited BK channels in HEK 293 cells expressing the human BKCa channel alpha subunit. Thus the carotid body contains both the enzymatic machinery and effector targets for H<sub>2</sub>S to function as a mediator of chemoreception.

There is also increasing evidence for H<sub>2</sub>S mediation of oxygen-sensing NEC cells in the fish gill (46). Bolus injection of H<sub>2</sub>S into the buccal (mouth) cavity produced a bradycardia similar to that produced by hypoxia (Fig. 3). Removal of the first pair of gill arches, the site of highest NEC density in trout and the homolog of the carotid body (38), greatly inhibited the H<sub>2</sub>S bradycardia, whereas removal of the second pair did not affect the H<sub>2</sub>S response. In addition, both hypoxia and H<sub>2</sub>S depolarized isolated zebrafish NECs (46). Thus H<sub>2</sub>S appears to be an active component of sensory transduction in a variety of vertebrate chemoreceptors.

#### **H<sub>2</sub>S and Myocardial O<sub>2</sub> Sensing**

There is considerable, but at times somewhat conflicting, evidence that H<sub>2</sub>S not only affects the heart but plays a role cardioprotection.


#### *H<sub>2</sub>S and cardiac function*

H<sub>2</sub>S has been reported to have negative inotropic effects in rats that appear to be mediated by opening of cardiac KATP channels (15). H<sub>2</sub>S-mediated inhibition of adenylate cyclase also produced negative inotropic and chronotropic effects in adrenergically-stimulated rat hearts, although it was proposed that this may protect the heart during hypoxia-mediated adrenergic stimulation (75). Daily injections of H<sub>2</sub>S reduced mortality in an adrenergically-stimulated myocardial ischemic injury model (14). In rats with a ligated left coronary artery H<sub>2</sub>S decreased mortality and PPG inhibition of CSE, which was prevalent in the myocardium, increased mortality (78).

#### *H<sub>2</sub>S and ischemic conditioning*

Preconditioning the heart with exogenous H<sub>2</sub>S mimics IPreC and IPostC and has been shown to exert a positive cardioprotective effect against RI (Fig. 4) (4, 10, 18, 19, 49–51). Even the H<sub>2</sub>S donor S-allylcysteine significantly lowered mortality and reduced infarct size in a rat model of acute





**FIG. 3. Evidence for H<sub>2</sub>S involvement in trout gill chemoreceptors.** Bolus 1 ml injections of H<sub>2</sub>S into the buccal cavity of an unanesthetized 600 g trout previously implanted with a pressure cannula in, and flow probe around, the ventral aorta produced bradycardia within 5–10 seconds that mimicked hypoxic bradycardia. Removal of the first pair of gills (-Gill 1), the primary location of chemoreceptors, decreased H<sub>2</sub>S responses relative to control fish, and fish without the second arches (-Gill 2). Mean  $\pm$  SE (N). *Inset* shows ventral aortic pressure (PvA) and cardiac output (CO) responses to single 5  $\mu$ mol H<sub>2</sub>S injection (*dotted line*). Adapted from ref. 46, with permission.

myocardial infarction. These studies have also shown that H<sub>2</sub>S-mediated cardioprotection utilizes similar activation pathways as IPreC, for example, activation of ERK and PI3K/Akt (19), activation of PKC $\alpha$ , PKC $\beta$ , and PKC $\delta$  (49, 51), activation of sarcolemmal but not mitochondrial KATP channels (4, 50), stimulation of cyclooxygenase-2 (COX-2; 18), and inhibition of NO production (50).

## Interaction Between Hypoxia and H<sub>2</sub>S

### Competition and enhancement

If H<sub>2</sub>S mediates O<sub>2</sub> sensing then it would be expected that vessels maximally stimulated by one would be refractory to the other, whereas submaximal activation by one stimulus would enhance responsiveness to the other. This has been demonstrated in several studies of conductance vessels. We (44) found that the hypoxic relaxation of rat thoracic aorta or hypoxic contraction of bovine pulmonary arteries or lamprey aorta was greatly diminished or abrogated by high (300  $\mu$ M) H<sub>2</sub>S and H<sub>2</sub>S relaxation of rat thoracic aorta or hypoxic contraction of bovine pulmonary arteries or lamprey aorta was greatly diminished or abrogated by extensive bubbling with 95% N<sub>2</sub>/5% CO<sub>2</sub> or 100% N<sub>2</sub> (mammal or lamprey respectively). We (45) also observed an increased H<sub>2</sub>S sensitivity in lamprey aortas when ambient Po<sub>2</sub> was  $\sim$ 20–30 mmHg and in hagfish aortas when bubbled with 100% N<sub>2</sub> (Po<sub>2</sub> not measured but presumed to be above  $>1$  mmHg based on previous studies). A similar increase in sensitivity to H<sub>2</sub>S-mediated vasodilation of rat aortas aerated with 95% N<sub>2</sub>/5% CO<sub>2</sub> was observed by Kiss *et al.* (27). Kiss *et al.* (27) also observed that in normoxia, but not hypoxia, low H<sub>2</sub>S (50  $\mu$ M) slightly contracted rat aortas, whereas higher H<sub>2</sub>S concentrations contracted both normoxic and hypoxic vessels. This is similar to the findings of Koenitzer *et al.* (28) in which low H<sub>2</sub>S concentrations (10–100  $\mu$ M) contracted rat aorta equilibrated with room air (200  $\mu$ M O<sub>2</sub>) and relaxed aortas when the Po<sub>2</sub> was  $\sim$ 30 mmHg (40  $\mu$ M O<sub>2</sub>). They (28) attributed the contraction to an unidentified oxidation product of H<sub>2</sub>S, rather than H<sub>2</sub>S itself. It is doubtful that an oxidation product mediates the response of the

lamprey or hagfish as H<sub>2</sub>S-mediated contractions were observed at both high and low O<sub>2</sub> (45).


### H<sub>2</sub>S metabolism and hypoxic responses

If H<sub>2</sub>S is to serve as an O<sub>2</sub> sensor, then alterations in H<sub>2</sub>S metabolism would be expected to affect hypoxic responses. Inhibition of hypoxic responses with inhibitors of H<sub>2</sub>S synthesis as well as augmentation of hypoxic responses with precursors of H<sub>2</sub>S synthesis has been demonstrated in several O<sub>2</sub>-sensing tissues.

In the rat aorta, the CSE inhibitor PPG completely inhibited hypoxic vasodilation (Fig. 5A), whereas the CBS inhibitor AOA, but not PPG, inhibited hypoxic vasoconstriction in bovine pulmonary arteries (Fig. 5B). Hydroxylamine, an inhibitor of both CSE and CBS, inhibited hypoxic vasoconstriction (44). Hydroxylamine also inhibited hypoxic vasoconstriction in the lamprey aorta (44). Hypoxic vasoconstriction in the hagfish dorsal aorta was inhibited by AOA but not by PPG or HA (45). In the mouse carotid body the CBS inhibitors AOA and HA abolished chemoreceptor afferent nerve discharge in response to hypoxia, whereas this was unaffected by the CSE inhibitor, PPG (56). Addition of compounds from which H<sub>2</sub>S can be generated, such as cysteine, glutathione and cysteine in combination with  $\alpha$ -ketoglutarate, have been shown to increase the magnitude of hypoxic vasoconstriction in the dorsal aorta of hagfish (45), lamprey (Fig. 5C; 44), bovine pulmonary artery (Fig. 5D; 44), and perfused rat lung (35).

Metabolic studies also suggest a role for endogenous H<sub>2</sub>S in RI and conditioning. Although ischemia attenuated H<sub>2</sub>S production, ischemic preconditioning (and exogenous H<sub>2</sub>S) restored H<sub>2</sub>S production during ischemia. CSE inhibitors PPG and BCA blocked the effect of IPreC and this blockade was reduced by coadministration of H<sub>2</sub>S (4, 7, 50). RI is significantly reduced in mice with cardiac-specific overexpression of CSE (10). Other H<sub>2</sub>S precursors also appear to mediate IPreC. The H<sub>2</sub>S donor, S-allylcysteine (SAC), injected daily for 7 days significantly increased myocardial CSE activity, lowered mortality, and reduced infarct size in a rat model of acute myocardial infarction, whereas PPG significantly lowered





**FIG. 4. Cardioprotection of H<sub>2</sub>S preconditioning.** (A) Immediate cardioprotective effects on electrically-induced  $[Ca^{2+}]_i$  transients in single ventricular myocytes. Preconditioning with NaHS for three cycles (3 min each cycle, separated by 5 min of recovery) significantly increased the amplitude of  $[Ca^{2+}]_i$  transients during ischemia/reperfusion. (B) Delayed cardioprotective effects on electrically-induced myocyte contraction in single ventricular myocytes. Isolated cardiac myocytes were treated with NaHS (100  $\mu$ M) for 30 min and then cultured in normal DMEM solution for 20 h, followed by ischemia/reperfusion insults. Representative tracings showing that H<sub>2</sub>S preconditioning increased myocyte twitch amplitude during ischemia/reperfusion. (C) *In vivo* study showing cardioprotection on myocardial infarct size in rats. A single bolus of NaHS (1  $\mu$ mol/kg body weight) administered 1 day before myocardial infarction produced a strong infarct-limiting effect. Mean  $\pm$  S.E.M. \*\*\* $p$  < 0.001 vs. vehicle preconditioning;  $n$  = 7–8. A adapted from ref. 4, with permission; B adapted from ref. 18, with permission; C adapted from ref. 49, with permission. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article at [www.liebertonline.com/ars](http://www.liebertonline.com/ars)).

myocardial CSE activity and increased mortality and size of the myocardial infarct (7). S-propargyl-cysteine, a structural analogue of SAC, provided preconditioning effects in both adult rat hearts and neonatal cardiomyocytes (67).


#### *Evidence for a direct inverse coupling between O<sub>2</sub> and H<sub>2</sub>S*

Until recently, measurement of tissue H<sub>2</sub>S production, like that of circulating H<sub>2</sub>S concentrations, were determined by indirect methods that usually entailed incubation of the sample for 30–90 min in a closed container, followed by terminating enzymatic reactions and either measurement of H<sub>2</sub>S directly or after trapping on an alkaline or zinc acetate wick (43). While these may (or may not) be satisfactory for measuring long-term H<sub>2</sub>S production, they do not appear suitable for measurement of H<sub>2</sub>S concentration in blood or tissues. The advent of amperometric (a.k.a. polarographic) H<sub>2</sub>S sensors permitted rapid, real-time measurement of H<sub>2</sub>S in unadulterated biological samples (43).

Using the amperometric H<sub>2</sub>S sensor, we examined the relationship between O<sub>2</sub> and H<sub>2</sub>S with respect to tissue H<sub>2</sub>S production and metabolism in O<sub>2</sub> sensing tissues and identification of the role of mitochondria in O<sub>2</sub>-dependent H<sub>2</sub>S

metabolism. We observed three consistent findings in a variety of tissues; (a) hydrogen sulfide was only produced under relatively anoxic conditions, (b) addition of precursors of H<sub>2</sub>S synthesis increased H<sub>2</sub>S production, and (c) addition of O<sub>2</sub> resulted in net H<sub>2</sub>S consumption. In minced trout heart (Fig. 6A and B) (74), cysteine produced a dose-dependent increase in the rate of H<sub>2</sub>S production. H<sub>2</sub>S production reverted to net consumption by addition of oxygen but resumed, presumably after the oxygen had been depleted. A similar cysteine-induced increase and O<sub>2</sub>-mediated inhibition of H<sub>2</sub>S production has been observed in the trout gill (46). Doeller *et al.* (8) also demonstrated that H<sub>2</sub>S was produced by a variety of rat tissues, including aortas, in buffer containing < 5  $\mu$ M O<sub>2</sub>, whereas H<sub>2</sub>S production was not observed in air-equilibrated (~200  $\mu$ M O<sub>2</sub>) buffer.

The relationship between H<sub>2</sub>S and O<sub>2</sub> is even more apparent when these gases are measured simultaneously. In homogenized rat lung (Fig. 6D), H<sub>2</sub>S increases after addition of  $\alpha$ -ketoglutarate, but production is converted to net consumption upon injection of small bubble of room air. Enough O<sub>2</sub> was present in this air bubble to theoretically increase O<sub>2</sub> concentration to ~8.5  $\mu$ M, however, the measured O<sub>2</sub> did not exceed 1  $\mu$ M, presumably due to a slight lag in gas diffusion out of the air bubble and concomitant O<sub>2</sub> consumption by the tissue. H<sub>2</sub>S



**FIG. 5.** Inhibition of hypoxic ( $N_2$ ) responses by inhibitors of  $H_2S$  synthesis (A, B) and stimulation of hypoxic responses by  $H_2S$  precursors (C, D). (A) Hypoxic relaxation of a norepinephrine-contracted (NE;  $10^{-6}$  moles  $l^{-1}$ ) rat thoracic aorta (TA) is significantly (\*) inhibited by the CSE inhibitor propargyl glycine (PPG). (B) Hypoxic contractions of bovine pulmonary arteries (PA) are not affected by propargyl glycine (P) but are increasingly inhibited by the CBS inhibitor aminooxyacetate (AOA) and the CBS + CSE inhibitor, hydroxylamine (H). (C) Hypoxic contraction of lamprey dorsal aorta (DA) is doubled by addition of 1 mM cysteine ( $N_2$  + Cys), whereas Cys does not affect a 80 mM KCl contraction (KCl + Cys). (D) Cys increases hypoxic contraction of bovine pulmonary artery compared to control (Con). Adapted from ref. 44, with permission.

production did not resume until oxygen had been nearly completely depleted from the chamber. Figure 6E shows the average production and consumption from three rats. The  $O_2$ -mediated inhibition of  $H_2S$  production observed in the rat lung is essentially identical to our observations that  $H_2S$  production/consumption by homogenized lung tissue from the cow and sea lion is tightly coupled to oxygen at low  $PO_2$  (48). The significance of these studies is that, while hypoxia has the opposite vasoactive effects on pulmonary arteries from terrestrial *versus* marine mammals, it has identical effects on  $H_2S$  metabolism. These studies also show that in normoxic conditions there is little, if any  $H_2S$  present.

The  $O_2$  tension at which oxygen becomes rate limiting in  $H_2S$  consumption in homogenized bovine lung tissue is shown in Fig. 7A.  $H_2S$  consumption remains constant until  $PO_2$  falls below 10 mmHg, and declines thereafter. The  $P_{50}$  for  $H_2S$  metabolism is  $\sim 4$  mmHg. Although there is still considerable debate on mitochondrial  $PO_2$ , this value appears to be close to that encountered during hypoxia. In a recent study, Mik *et al.* (37) measured mitochondrial oxygen tension in rat hearts *in vivo* and observed that when arterial  $PO_2$  ( $P_{aO_2}$ ) was normal, 10% of the mitochondria had a  $PO_2$  of 5 mmHg or lower, 30% had a  $PO_2$  of 5–15 mmHg, and the rest were  $>15$  mmHg. When  $P_{aO_2}$  was reduced to 40 mmHg by inspiring 10% oxygen, over 45% of the mitochondria had a  $PO_2$  of 5 mmHg or lower and 10% had a  $PO_2$  of 5–15 mmHg. Thus this level of hypoxia places progressively more mitochondria in a  $O_2$ -deficient environment that is not sufficient for  $H_2S$  metabolism.


The percent activity of  $H_2S$  inactivation can be expressed as a function of  $PO_2$  and compared to other potential  $O_2$  sensors (Fig. 8) (69). It becomes evident that the metabolism of  $H_2S$  has

two advantages over the other sensors, it is more efficient than most of the other proposed mechanisms in the range of cytosolic/mitochondrial  $PO_2$ , and it has a greater dynamic range going from complete  $H_2S$  consumption above 15 mmHg to almost no consumption at 2 mmHg. A similar comparison of the ability of purified bovine heart mitochondria to metabolize  $H_2S$  is also shown in Fig. 8 and shows that mitochondria are more efficient at lower  $PO_2$ . This curve looks to be very similar to, and appears to be a continuation of, the curve for mitochondrial cytochrome aa3 as described by Ward (69) and also depicted in Fig. 8. While these studies will need to be repeated with other tissues, they are, nevertheless, suggestive of an efficient sensing system operating at the level of the mitochondria.

## **$H_2S$ Signaling**

### *Autocrine, paracrine, or endocrine*

Whether  $H_2S$  serves as a circulating molecular signal or is a local paracrine or autocrine messenger has been the subject of recent interest and controversy (43, 62) and is briefly summarized here. Nearly all studies published prior to 2000 reported plasma or blood  $H_2S$  concentrations  $<1 \mu\text{mol } l^{-1}$ . Since then, however, the number of studies showing plasma  $H_2S$   $>10 \mu\text{mol } l^{-1}$  has steadily increased and there are now a half dozen reports of plasma  $H_2S$   $\sim 300 \mu\text{mol } l^{-1}$ , even though essentially all of these studies are on relatively few mammals, namely rats and mice (summarized in 43). However, there are a number of arguments against these elevated plasma titers. First, even  $1 \mu\text{mol } l^{-1}$   $H_2S$  in buffer is readily detected by the human nose (13) and  $>10 \mu\text{mol } l^{-1}$  should be obvious in plasma. Second, being a gas,  $H_2S$  will readily equilibrate



**FIG. 6.** Oxygen-dependent H<sub>2</sub>S production and consumption in O<sub>2</sub>-sensitive tissues measured in real-time with a amperometric H<sub>2</sub>S sensor. (A, B) H<sub>2</sub>S production (as total sulfide) by minced trout heart increases with increasing concentrations of cysteine (Cys; at P<sub>O<sub>2</sub></sub> ~0). Injection of oxygen (O<sub>2</sub>) sufficient to theoretically raise oxygen concentration to 100 μmol/l transiently results in net H<sub>2</sub>S consumption. H<sub>2</sub>S production resumes after the oxygen is consumed. (A) Single representative trace, (B) mean ± SE (*n* = 4). (C) H<sub>2</sub>S production (as total sulfide) by homogenized trout gill occurs spontaneously after addition of pyridoxal 5'-phosphate (PLP, 1 mM); injection of air (theoretical O<sub>2</sub> concentration 10 μmol/l) produces net H<sub>2</sub>S consumption. Addition of Cys increases H<sub>2</sub>S production and a second injection of air produces net H<sub>2</sub>S consumption; w, wash. (D, E) Relationship between O<sub>2</sub> concentration (dotted line) and H<sub>2</sub>S production (as total sulfide; solid line) by homogenized rat lung. (D) In anoxia, H<sub>2</sub>S production increases after addition of α-ketoglutarate (α-Kg, 1 mM), in the presence of Cys (1 mM). Injection of oxygen (O<sub>2</sub>) results in net H<sub>2</sub>S consumption. When all O<sub>2</sub> is consumed, H<sub>2</sub>S production is restored. (E) Net rate of H<sub>2</sub>S production (positive values) or consumption (negative values) as a function of substrate and O<sub>2</sub>. (F) H<sub>2</sub>S consumption by purified bovine heart mitochondria; *left trace* shows rapid fall in H<sub>2</sub>S concentration after addition of mitochondria (mitos). The rapid fall in H<sub>2</sub>S concentration is prevented when the mitochondria are heat killed prior to addition (*right trace*); w, wash with H<sub>2</sub>S-free buffer. A, B adapted from ref. 74, with permission; C adapted from ref. 46, with permission; D–F, Whitfield and Olson unpublished.

across the alveolar membranes (22) and should be readily detected in exhaled air, but it is not. Third, there is not enough cysteine in the body to sustain the predicted loss of H<sub>2</sub>S in exhaled air for even a fraction of one day (13). Fourth, modern methods of H<sub>2</sub>S analysis such as the polarographic (amperimetric) sensor (74) and HPLC separation (61) have failed to confirm these high levels and have reported plasma H<sub>2</sub>S < 1 μmol l<sup>-1</sup>, and often undetectable. Fifth, measurements in real-time with the polarographic sensor of H<sub>2</sub>S in fresh blood from mammals and fish, or in fish fitted with an extracorporeal loop have shown that exogenous H<sub>2</sub>S rapidly disappears from the plasma (46, 74). Sixth, studies on tissue metabolism of H<sub>2</sub>S (see section on Interaction between Hypoxia and H<sub>2</sub>S, above) clearly show that in the presence of oxygen H<sub>2</sub>S is readily consumed by tissues and under normoxic conditions there would be little if any favorable H<sub>2</sub>S gradient from the tissue to blood. In fact, it has been shown that H<sub>2</sub>S is essentially absent from tissues (13). Seventh, thus

far, all attempts to free H<sub>2</sub>S from a potential acid-labile or sulfate sulfur carrier in either plasma or red blood cells has failed to do so, even after adding exogenous H<sub>2</sub>S (43). Sources of error that could potentially result in elevated H<sub>2</sub>S values are beginning to be examined. The strongly alkaline antioxidant buffer mixed with plasma to drive all H<sub>2</sub>S to S<sup>2-</sup> for measurement with the sulfide ion selective electrode has been shown to generate free sulfide from plasma proteins and even from albumin solutions (74). The direct methylene blue method, which was originally developed for measuring H<sub>2</sub>S in aqueous samples (59), is also commonly used for plasma H<sub>2</sub>S measurements, even though it employs a strong acid and was never validated for measuring plasma or blood. It is evident that a standardized (and validated) approach to plasma H<sub>2</sub>S measurements needs to be adopted. In the meantime, the most recent evidence with new methodologies supports the earlier (pre-2000) reports that H<sub>2</sub>S, either free or bound to a carrier, does not circulate in the plasma. H<sub>2</sub>S should be




FIG. 7. (A) Relationship between  $O_2$  and  $H_2S$  consumption as a function of oxygen concentration in bovine lung homogenate.  $O_2$  and  $H_2S$  were continuously measured with amperometric sensors. The rate of  $H_2S$  consumption decreased when  $O_2$  concentration fell below 10  $\mu M$ . (B)  $O_2$ -dependent  $H_2S$  consumption by bovine lung homogenate from panel A plotted as a function of  $O_2$  concentrations (length of arrows indicates range of reported  $[O_2]$ ) in tissue and cells. There is sufficient oxygen from the vasculature to the cytosol and even normoxic mitochondria to effectively consume  $H_2S$  as rapidly as it is generated. During hypoxia, a fall mitochondrial  $O_2$  will decrease  $H_2S$  consumption. A redrawn after ref. 48; B,  $O_2$  concentrations from pre-capillary arterioles to cytosol redrawn from ref. 69 with mitochondrial  $O_2$  concentration estimated to range from cytosolic to 0 (37).

considered an autocrine or paracrine signaling molecule in the cardiovascular system.

Because  $H_2S$  does not appear to circulate, perhaps the most important questions to be resolved are; what is the intracellular  $H_2S$  concentration, how is it affected by various stimuli, and is there an intracellular compartmentalization of  $H_2S$  signaling? To date, there are no methods for measuring these parameters. It is even difficult to estimate intracellular  $H_2S$  concentration based on the concentration of exogenous  $H_2S$  necessary to elicit various effector responses. Most reports of the physiological/pharmacological effects of  $H_2S$  have recorded responses in the tens to hundreds of  $\mu mol \text{ l}^{-1}$ . While it is possible that these concentrations could be achieved in very localized areas within the cell, there is no evidence to support or refute this. It is also possible that supraphysiological concentrations of exogenous  $H_2S$  are necessary to offset the very efficient intracellular mechanisms of  $H_2S$  oxidation. There is some support for this latter hypothesis in that both Koenitzer *et al.* (28) and Olson *et al.* (45) have shown that the apparent vascular sensitivity to  $H_2S$  is increased at low  $P_{O_2}$ .

#### Mechanisms of action

At first glance, the myriad of effects that have been attributed to  $H_2S$  in a variety of biological systems that have been studied would suggest that the potential mechanisms of action of  $H_2S$  in the cardiovascular system are also seemingly limitless (62). Some of this no doubt is due to the concentrations of  $H_2S$  that have been used to elicit these responses (see

above) and whether the observed effects are physiological or pharmacological. This question will largely remain unanswered until actual intracellular  $H_2S$  concentrations and sites of localized activity are known. At the risk of omission, some of the more prevalent mechanisms of  $H_2S$  action cited in Szabó, (62) and further examined in a recent paper by Muzaffar *et al.* (40) are shown in Fig. 9. The physiological importance of these remains to be defined.


#### Anecdotal Evidence for $H_2S$ and $O_2$ Sensing

##### Geochemical evidence and evolution

**Relationship between  $O_2$  and  $H_2S$  in the environment.**  $O_2$  and  $H_2S$  are mutually exclusive in the environment, the presence of one generally precludes the existence of the other. This is evident on the geological time scale; sulfidic oceans prevalent in the reducing and  $O_2$ -deficient earth, disappeared as atmospheric  $O_2$  increased, and then returned periodically as a result of upwelling of  $H_2S$ -rich deep ocean sediments during episodic declines in oceanic  $O_2$  (30). This relationship is also evident in the present day, albeit in more restricted conditions, and appears as a mobile boundary layer between  $H_2S$ -rich anoxic and  $H_2S$ -deficient oxygenated water that changes with the level of oxygenation, receding when  $O_2$  increases and growing when  $O_2$  falls (3). By inference, the presence of one of these gases is indicative of the absence of the other.

**Natural selection for hypoxia and  $H_2S$  tolerance.** Periodic increases in ambient  $H_2S$  associated with a global decrease in






**FIG. 8. Theoretical activity of potential O<sub>2</sub> sensors over physiologically encountered oxygen concentrations.** H<sub>2</sub>S fills a gap in sensitivity in the Po<sub>2</sub> range most likely encountered by the cytoplasmic/mitochondria environment during hypoxia. Abbreviations: Cyt aa3, mitochondrial cytochromes a and a3; CYP $\omega$ , cytochrome P450 mono-oxygenase  $\omega$ ; FIH-1, factor inhibiting hypoxia inducible factor-1 $\alpha$ , (HIF-1 $\alpha$ ); H<sub>2</sub>S, hydrogen sulfide; HO-2, heme oxygenase 2; NOX2, NADPH oxidase; PHD, prolyl hydroxylase domain proteins involved in O<sub>2</sub>-dependent hydroxylation of protein residues on HIF-1 $\alpha$ . Redrawn and modified from ref. 69 with inclusion of H<sub>2</sub>S data from Fig. 7A and the effect of O<sub>2</sub> on H<sub>2</sub>S consumption by purified bovine mitochondria (mito; 48). Po<sub>2</sub> response curve of hypoxic contraction of isolated bovine conductance pulmonary arteries (CPA; dashed line) is shown for comparison (48).

O<sub>2</sub> have been proposed to cause several if not more of the great extinctions. Most notable among these was the mass extinction at the Permian-Triassic boundary that saw fall in atmospheric O<sub>2</sub> to as low as 13% (Po<sub>2</sub> ~100 mmHg) and destroyed ~70% of life on land and 90% of life in the water (20). Animals that passed through this gauntlet of natural selection, and those more recent, no doubt possess special adaptations to hypoxia (12, 20). It would seem that they would also have been selected for H<sub>2</sub>S tolerance.

**Origin of mitochondria**—The key factor in H<sub>2</sub>S-mediated O<sub>2</sub> sensing? Searcy (57) proposed that mitochondria originated from sulfide (H<sub>2</sub>S)-oxidizing thermophilic bacteria and the nucleocytoplasm from sulfide-reducing Archaea. This supports the hypothesis that H<sub>2</sub>S production and oxidation are compartmentalized intracellularly and that the mechanism for constitutive production of H<sub>2</sub>S and its oxygen-dependent inactivation by mitochondria is a common feature of all eukaryotic cells.

#### Other H<sub>2</sub>S–hypoxia interactions

A number of other studies have suggested the relationship between H<sub>2</sub>S and hypoxia. Hypoxia increases H<sub>2</sub>S production in the rat uterus (52), a tissue implicated in a variety of



**FIG. 9. Potential short-term effectors of H<sub>2</sub>S activity in the cardiovascular system.** The best characterized cardiovascular effector is an H<sub>2</sub>S-mediated opening of ATP-sensitive potassium channels (K<sub>ATP</sub>) which hyperpolarizes the cell and endothelial Ca<sup>2+</sup>-dependent K<sup>+</sup> (K<sub>Ca</sub>), and H<sub>2</sub>S-mediated charybdotoxin/apamin-sensitive K<sup>+</sup> channels. H<sub>2</sub>S may also inhibit NADPH oxidase (NOX-1), adenylyl cyclase (AC), and nitric oxide synthase (the endothelial form, eNOS is shown here). In addition, H<sub>2</sub>S may directly bind, and therefore lower the concentration of, nitric oxide (NO) or combine with NO to form a nitrosothiol (SNO), it may lower the redox potential of the cell by combining with superoxide (O<sub>2</sub><sup>-</sup>) or other reactive oxygen species (ROS). Because H<sub>2</sub>S is a weak acid and is in equilibrium forming H<sup>+</sup> and HS<sup>-</sup>, H<sub>2</sub>S may lower intracellular pH and the HS<sup>-</sup> may mimic or compete with Cl<sup>-</sup> and HCO<sub>3</sub><sup>-</sup> in a variety of ion channels and transporters.

physiological and pathological responses to hypoxia (6). We have observed that hypoxia and H<sub>2</sub>S have similar actions and appear to act through a common mechanism in the trout urinary bladder (9). Recent studies on the molecular mechanism of H<sub>2</sub>S signaling suggest that H<sub>2</sub>S may activate proteins by sulfhydration of cysteine residues and this process is far more extensive under hypoxic conditions (A.K.Mustafa, personal communication).

#### Concluding Comments

The excitement surrounding the myriad of potential physiological and pathophysiological actions of H<sub>2</sub>S that are beginning to be examined is understandable. Potential therapies from H<sub>2</sub>S-laden aspirin to suspended animation and perhaps pulmonary hypertension, myocardial infarction, and stroke are already garnering emotional if not financial support. But we also need to critically examine what is physiological and what is not. This review is a case in point. On one hand, it describes numerous studies of the effects of exogenous H<sub>2</sub>S, and on the other it evaluates hypoxia-driven H<sub>2</sub>S production as the signaling entity. But there is often 100-fold or greater H<sub>2</sub>S concentration difference between the two. Is this because extra exogenous H<sub>2</sub>S is required to overload endogenous metabolism, or are we really looking at pharmacological effects? These are questions we need to keep asking ourselves, and hopefully resolve with better methodology.

## Acknowledgments

The authors wish to acknowledge the numerous colleagues—Drs. R. Dombkowski, D. Duff, D. Emenim, M. Russell, J. Madden, S. Perry, and N. Skovgaard—and students—M. Healy, E. Kreimier, T. Mudigonda, M. Perks, S. Head, N. Whitfield, and F. Verdial—who participated in this research. Supported in part by National Science Foundation Grant Nos. IBN 0235223 and IOS 0641436.

## References

- Ali MY, Ping CY, Mok YY, Ling L, Whiteman M, Bhatia M, and Moore PK. Regulation of vascular nitric oxide *in vitro* and *in vivo*: A new role for endogenous hydrogen sulphide? *Br J Pharmacol* 149: 625–634, 2006.
- Aslami H, Schultz MJ, and Juffermans NP. Potential applications of hydrogen sulfide-induced suspended animation. *Curr Med Chem* 16: 1295–1303, 2009.
- Bagarinao T. Sulfide as an environmental factor and toxicant: tolerance and adaptations in aquatic organisms. *Aquat Toxicol* 24: 21–62, 1992.
- Bian JS, Yong QC, Pan TT, Feng ZN, Ali MY, Zhou S, and Moore PK. Role of hydrogen sulfide in the cardioprotection caused by ischemic preconditioning in the rat heart and cardiac myocytes. *J Pharmacol Exp Ther* 316: 670–678, 2006.
- Biscoe TJ and Duchon MR. Responses of type I cells dissociated from the rabbit carotid body to hypoxia. *J Physiol* 428: 39–59, 1990.
- Burton GJ. Oxygen, the Janus gas; Its effects on human placental development and function. *J Anat* 215: 27–35, 2009.
- Chuah SC, Moore PK, and Zhu YZ. S-allylcysteine mediates cardioprotection in an acute myocardial infarction rat model via a hydrogen sulfide-mediated pathway. *Am J Physiol Heart Circ Physiol* 293: H2693–H2701, 2007.
- Doeller JE, Isbell TS, Benavides G, Koenitzer J, Patel H, Patel RP, Lancaster JR, Darley-Usmar VM, and Kraus DW. Polarographic measurement of hydrogen sulfide production and consumption by mammalian tissues. *Anal Biochem* 341: 40–51, 2005.
- Dombkowski RA, Doellman MM, Head SK, and Olson KR. Hydrogen sulfide mediates hypoxia-induced relaxation of trout urinary bladder smooth muscle. *J Exp Biol* 209: 3234–3240, 2006.
- Elrod JW, Calvert JW, Morrison J, Doeller JE, Kraus DW, Tao L, Jiao X, Scalia R, Kiss L, Szabo C, Kimura H, Chow CW, and Lefer DJ. Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. *Proc Natl Acad Sci USA* 104: 15560–15565, 2007.
- Evans AM. AMP-activated protein kinase underpins hypoxic pulmonary vasoconstriction and carotid body excitation by hypoxia in mammals. *Exp Physiol* 91: 821–827, 2006.
- Flück M, Webster KA, Graham JB, Giomi F, Gerlach F, and Schmitz A. Coping with cyclic oxygen availability: evolutionary aspects. *Integr Comp Biol* 47: 524–531, 2007.
- Furne J, Saeed A, and Levitt MD. Whole tissue hydrogen sulfide concentrations are orders of magnitude lower than presently accepted values. *Am J Physiol Regul Integr Comp Physiol* 295: R1479–R1485, 2008.
- Geng B, Chang L, Pan C, Qi Y, Zhao J, Pang Y, Du J, and Tang C. Endogenous hydrogen sulfide regulation of myocardial injury induced by isoproterenol. *Biochem Biophys Res Commun* 318: 756–763, 2004.
- Geng B, Yang J, Qi Y, Zhao J, Pang Y, Du J, and Tang C. H<sub>2</sub>S generated by heart in rat and its effects on cardiac function. *Biochem Biophys Res Commun* 313: 362–368, 2004.
- Hausenloy DJ and Yellon DM. Preconditioning and post-conditioning: United at reperfusion. *Pharmacol Ther* 116: 173–191, 2007.
- Hildebrandt TM and Grieshaber MK. Three enzymatic activities catalyze the oxidation of sulfide to thiosulfate in mammalian and invertebrate mitochondria. *FEBS J* 275: 3352–3361, 2008.
- Hu LF, Pan TT, Neo KL, Yong QC, and Bian JS. Cyclooxygenase-2 mediates the delayed cardioprotection induced by hydrogen sulfide preconditioning in isolated rat cardiomyocytes. *Pflügers Arch* 455: 971–978, 2008.
- Hu Y, Chen X, Pan TT, Neo KL, Lee SW, Khin ES, Moore PK, and Bian JS. Cardioprotection induced by hydrogen sulfide preconditioning involves activation of ERK and PI3K/Akt pathways. *Pflügers Arch* 455: 607–616, 2008.
- Huey RB and Ward PD. Hypoxia, global warming, and terrestrial late Permian extinctions. *Science* 308: 398–401, 2005.
- Ignarro LJ, Burke TM, Wood KS, Wolin MS, and Kadowitz PJ. Association between cyclic GMP accumulation and acetylcholine-elicited relaxation of bovine intrapulmonary artery. *J Pharmacol Exp Ther* 228: 682–690, 1984.
- Insko MA, Deckwerth TL, Hill P, Toombs CF, and Szabo C. Detection of exhaled hydrogen sulphide gas in rats exposed to intravenous sodium sulphide. *Br J Pharmacol* 157: 944–951, 2009.
- Jeong SO, Pae HO, Oh GS, Jeong GS, Lee BS, Lee S, Kim DY, Rhew HY, Lee KM, and Chung HT. Hydrogen sulfide potentiates interleukin-1 $\beta$ -induced nitric oxide production via enhancement of extracellular signal-regulated kinase activation in rat vascular smooth muscle cells. *Biochem Biophys Res Commun* 345: 938–944, 2006.
- Jonz MG, Fearon IM, and Nurse CA. Neuroepithelial oxygen chemoreceptors of the zebrafish gill. *J Physiol* 560: 737–752, 2004.
- Julian D, Statile JL, Wohlgemuth SE, and Arp AJ. Enzymatic hydrogen sulfide production in marine invertebrate tissues. *Comp Biochem Physiol [A] Mol Integr Physiol* 133: 105–115, 2002.
- Kemp PJ, Lewis A, Hartness ME, Searle GJ, Miller P, O'Kelly I, and Peers C. Airway chemotransduction: from oxygen sensor to cellular effector. *Am J Respir Crit Care Med* 166: S17–S24, 2002.
- Kiss L, Deitch EA, and Szabo C. Hydrogen sulfide decreases adenosine triphosphate levels in aortic rings and leads to vasorelaxation via metabolic inhibition. *Life Sci* 83: 589–594, 2008.
- Koenitzer JR, Isbell TS, Patel HD, Benavides GA, Dickinson DA, Patel RP, Darley-Usmar VM, Lancaster JR, Jr., Doeller JE, and Kraus DW. Hydrogen sulfide mediates vasoactivity in an O<sub>2</sub>-dependent manner. *Am J Physiol Heart Circ Physiol* 292: H1953–H1960, 2007.
- Kubo S, Doe I, Kurokawa Y, Nishikawa H, and Kawabata A. Direct inhibition of endothelial nitric oxide synthase by hydrogen sulfide: Contribution to dual modulation of vascular tension. *Toxicology* 232: 138–146, 2007.
- Kump LR, Pavlov A, and Arthur MA. Massive release of hydrogen sulfide to the surface ocean and atmosphere during intervals of oceanic anoxia. *Geology* 33: 397–400, 2005.
- Lee SW, Cheng y, Moore PK, and Bian JS. Hydrogen sulphide regulates intracellular pH in vascular smooth muscle cells. *Biochem Biophys Res Commun* 358: 1142–1147, 2007.



32. Lim JJ, Liu YH, Khin ES, and Bian JS. Vasoconstrictive effect of hydrogen sulfide involves downregulation of cAMP in vascular smooth muscle cells. *Am J Physiol Cell Physiol* 295: C1261–C1270, 2008.
33. Lopez-Barneo J, del TR, Levitsky KL, Chiara MD, and Ortega-Saenz P. Regulation of oxygen sensing by ion channels. *J Appl Physiol* 96: 1187–1195, 2004.
34. Maclean KN and Kraus JP. Hydrogen sulfide production and metabolism in mammalian tissues. In: *Signal Transduction and the Gasotransmitters*, edited by Wang R. Totowa, NJ: Humana Press, Inc., 2004, p. 275–292.
35. Madden JA, Olson KR, and Roerig DL. Precursors of hydrogen sulfide synthesis augment acute hypoxic pulmonary vasoconstriction in the intact lung. *Am J Respir Crit Care Med* 177: A252, 2008.
36. Madden JA, Vadula MS, and Kurup VP. Effects of hypoxia and other vasoactive agents on pulmonary and cerebral artery smooth muscle cells. *Am J Physiol Lung Cell Mol Physiol* 263: L384–L393, 1992.
37. Mik EG, Ince C, Eerbeek O, Heinen A, Stap J, Hooibrink B, Schumacher CA, Balestra GM, Johannes T, Beek JF, Nieuwenhuis AF, van HP, Spaan JA, and Zuurbier CJ. Mitochondrial oxygen tension within the heart. *J Mol Cell Cardiol* 46: 943–951, 2009.
38. Milsom WK and Burleson ML. Peripheral arterial chemoreceptors and the evolution of the carotid body. *Respir Physiol Neurobiol* 157: 4–11, 2007.
39. Moudgil R, Michelakis ED, and Archer SL. Hypoxic pulmonary vasoconstriction. *J Appl Physiol* 98: 390–403, 2005.
40. Muzaffar S, Shukla N, Bond M, Newby AC, Angelini GD, Sparatore A, Del SP, and Jeremy JY. Exogenous hydrogen sulfide inhibits superoxide formation, NOX-1 expression and Rac1 activity in human vascular smooth muscle cells. *J Vasc Res* 45: 521–528, 2008.
41. Nurse CA, Buttigieg J, Thompson R, Zhang M, and Cutz E. Oxygen sensing in neuroepithelial and adrenal chromaffin cells. *Novartis Found Symp* 272: 106–114, 2006.
42. Olson KR. Hydrogen sulfide and oxygen sensing: Implications in cardiorespiratory control. *J Exp Biol* 211: 2008.
43. Olson KR. Is hydrogen sulfide a circulating "gasotransmitter" in vertebrate blood? *Biochim Biophys Acta* 1787: 856–863, 2009.
44. Olson KR, Dombkowski RA, Russell MJ, Doellman MM, Head SK, Whitfield NL, and Madden JA. Hydrogen sulfide as an oxygen sensor/transducer in vertebrate hypoxic vasoconstriction and hypoxic vasodilation. *J Exp Biol* 209: 4011–4023, 2006.
45. Olson KR, Forgan LG, Dombkowski RA, and Forster ME. Oxygen dependency of hydrogen sulfide-mediated vasoconstriction in cyclostome aortas. *J Exper Biol* 211: 2205–2213, 2008.
46. Olson KR, Healy M, Qin J, Skovgaard N, Vulesevic B, Duff DW, Whitfield NL, Yang G, Wang R, and Perry SF. Hydrogen sulfide as an oxygen sensor in trout gill chemoreceptors. *Am J Physiol Regul Integr Comp Physiol* 295: R669–R680, 2008.
47. Olson KR, Russell MJ, and Forster ME. Hypoxic vasoconstriction of cyclostome systemic vessels: The physiological antecedent of hypoxic pulmonary vasoconstriction? *Am J Physiol Regul Integr Comp Physiol* 280: R198–R206, 2001.
48. Olson KR, Whitfield NL, Bearden SE, St. Ledger J, Nilson E, Gao Y, and Madden JA. Hypoxic pulmonary vasodilation: A paradigm shift with a hydrogen sulfide mechanism. *Am J Physiol Regul Integr Comp Physiol* 2009. (Epub: doi:10.1152/ajpregu.00576.2009)
49. Pan TT, Chen YQ, and Bian JS. All in the timing: A comparison between the cardioprotection induced by H(2)S preconditioning and post-infarction treatment. *Eur J Pharmacol* 616: 160–165, 2009.
50. Pan TT, Feng ZN, Lee SW, Moore PK, and Bian JS. Endogenous hydrogen sulfide contributes to the cardioprotection by metabolic inhibition preconditioning in the rat ventricular myocytes. *J Mol Cell Cardiol* 40: 119–130, 2006.
51. Pan TT, Neo KL, Hu LF, Yong QC, and Bian JS. H<sub>2</sub>S preconditioning-induced PKC activation regulates intracellular calcium handling in rat cardiomyocytes. *Am J Physiol Cell Physiol* 294: C169–C177, 2008.
52. Patel P, Vathish M, Heptinstall J, Wang R, and Carson RJ. The endogenous production of hydrogen sulphide in intrauterine tissues. *Reprod Biol Endocrinol* 7: 10, 2009.
53. Peers C and Kemp PJ. Acute oxygen sensing: Diverse but convergent mechanisms in airway and arterial chemoreceptors. *Respir Res* 2: 145–149, 2001.
54. Prabhakar NR. O<sub>2</sub> sensing at the mammalian carotid body: Why multiple O<sub>2</sub> sensors and multiple transmitters? *Exp Physiol* 91: 17–23, 2006.
55. Ramirez JM, Folkow LP, and Blix AS. Hypoxia tolerance in mammals and birds: from the wilderness to the clinic. *Annu Rev Physiol* 69: 113–143, 2007.
56. Rong W, Sun B, Wang X, Li Q, Jin Z, Dong L, and Shi W. Oxygen-sensing through production of hydrogen sulphide in peripheral chemoreceptors. *Autonomic Neurosci* 135: 68–69, 2007.
57. Searcy DG. Metabolic integration during the evolutionary origin of mitochondria. *Cell Res* 13: 229–238, 2003.
58. Shibuya N, Tanaka M, Yoshida M, Ogasawara Y, Togawa T, Ishii K, and Kimura H. 3-Mercaptopyrivate sulfurtransferase produces hydrogen sulfide and bound sulfane sulfur in the brain. *Antioxid Redox Signal* 11: 703–714, 2009.
59. Siegel LM. A direct microdetermination for sulfide. *Anal Biochem* 11: 126–132, 1965.
60. Sommer N, Dietrich A, Schermuly RT, Ghofrani HA, Gudermann T, Schulz R, Seeger W, Grimminger F, and Weissmann N. Regulation of hypoxic pulmonary vasoconstriction: Basic mechanisms. *Eur Respir J* 32: 1639–1651, 2008.
61. Sparatore A, Perrino E, Tazzari V, Giustarini D, Rossi R, Rossoni G, Erdman K, Schroder H, and Del SP. Pharmacological profile of a novel H(2)S-releasing aspirin. *Free Radic Biol Med* 46: 586–592, 2009.
62. Szabo C. Hydrogen sulphide and its therapeutic potential. *Nat Rev Drug Discov* 6: 917–935, 2007.
63. Tapuria N, Kumar Y, Habib MM, Abu AM, Seifalian AM, and Davidson BR. Remote ischemic preconditioning: A novel protective method from ischemia reperfusion injury—A review. *J Surg Res* 150: 304–330, 2008.
64. Telezhkin V, Brazier SP, Cayzac S, Muller CT, Riccardi D, and Kemp PJ. Hydrogen sulfide inhibits human BK(Ca) channels. *Adv Exp Med Biol* 648: 65–72, 2009.
65. Thorne GD, Ishida Y, and Paul RJ. Hypoxic vasorelaxation: Ca<sup>2+</sup>-dependent and Ca<sup>2+</sup>-independent mechanisms. *Cell Calcium* 36: 201–208, 2004.
66. Vinten-Johansen J. Postconditioning: A mechanical maneuver that triggers biological and molecular cardioprotective responses to reperfusion. *Heart Fail Rev* 12: 235–244, 2007.
67. Wang Q, Liu HR, Mu Q, Rose P, and Zhu YZ. S-propargyl-cysteine protects both adult rat hearts and neonatal cardiomyocytes from ischemia/hypoxia injury: The contribution of

- the hydrogen sulfide-mediated pathway. *J Cardiovasc Pharmacol* 54: 139–146, 2009.
68. Wang R. Two's company, three's a crowd: Can H<sub>2</sub>S be the third endogenous gaseous transmitter? *FASEB J* 16: 1792–1798, 2002.
  69. Ward JP. Oxygen sensors in context. *Biochim Biophys Acta* 1777: 1–14, 2008.
  70. Ward JP, Weir EK, and Archer SL. Hypoxic pulmonary vasoconstriction is /is not mediated by increased production of reactive oxygen species. *J Appl Physiol* 101: 993–998, 2006.
  71. Webb GD, Lim LH, Oh VM, Yeo SB, Cheong YP, Ali MY, El OR, Lee CN, Wong PS, Caleb MG, Salto-Tellez M, Bhatia M, Chan ES, Taylor EA, and Moore PK. Contractile and vasorelaxant effects of hydrogen sulfide and its biosynthesis in the human internal mammary artery. *J Pharmacol Exp Ther* 324: 876–882, 2008.
  72. Weir EK, Obrezhtchikova M, Vargese A, Cabrera JA, Peterson DA, and Hong Z. Mechanisms of oxygen sensing: A key to therapy of pulmonary hypertension and patent ductus arteriosus. *Br J Pharmacol* 155: 300–307, 2008.
  73. Whiteman M, Li L, Kostetski I, Chu SH, Siau JL, Bhatia M, and Moore PK. Evidence for the formation of a novel nitrosothiol from the gaseous mediators nitric oxide and hydrogen sulphide. *Biochem Biophys Res Commun* 343: 303–310, 2006.
  74. Whitfield NL, Kreimier EL, Verdial FC, Skovgaard N, and Olson KR. A reappraisal of H<sub>2</sub>S/sulfide concentration in vertebrate blood and its potential significance in ischemic preconditioning and vascular signaling. *Am J Physiol Regul Integr Comp Physiol* 294: R1930–R1937, 2008.
  75. Yong QC, Pan TT, Hu LF, and Bian JS. Negative regulation of beta-adrenergic function by hydrogen sulphide in the rat hearts. *J Mol Cell Cardiol* 44: 701–710, 2008.
  76. Zhao W and Wang R. H<sub>2</sub>S-induced vasorelaxation and underlying cellular and molecular mechanisms. *Am J Physiol Heart Circ Physiol* 283: H474–H480, 2002.
  77. Zhong G, Chen F, Cheng y, Tang C, and Du J. The role of hydrogen sulfide generation in the pathogenesis of hypertension in rats induced by inhibition of nitric oxide synthase. *J Hypertens* 21: 1897–1885, 2003.
  78. Zhu YZ, Wang ZJ, Ho P, Loke YY, Zhu YC, Huang SH, Tan CS, Whiteman M, Lu J, and Moore PK. Hydrogen sulfide and its possible roles in myocardial ischemia in experimental rats. *J Appl Physiol* 102: 261–268, 2007.

Address correspondence to:

Kenneth R. Olson, Ph.D.

Indiana University School of Medicine—South Bend

1234 Notre Dame Avenue

South Bend, IN 46617

E-mail: olson.1@nd.edu

Date of first submission to ARS Central, September 25, 2009;  
date of acceptance, October 3, 2009.

### Abbreviations Used

3-MST = 3-mercaptopyruvate sulfurtransferase  
 $\alpha$ -KG =  $\alpha$ -ketoglutarate  
 Akt = genes coding for serine/threonine-specific protein kinases  
 AMP = adenosine monophosphate  
 AOA = aminooxyacetate  
 BCA =  $\beta$ -cyanoalanine  
 BKCa = large-conductance Ca<sup>2+</sup>-dependent K<sup>+</sup> channels  
 cADPR = cyclic adenosine diphosphate-ribose  
 CBS = cystathionine  $\beta$ -synthase  
 COPD = chronic obstructive lung disease  
 COX-2 = cyclooxygenase-2  
 CPA = conductance pulmonary arteries  
 CSE = cystathionine  $\lambda$ -lyase  
 eNOS = endothelial nitric oxide synthase  
 ERK1/2 = extracellular regulated kinase ½  
 HA = hydroxylamine  
 HIF = hypoxia inducible factor  
 HO-2 = heme oxygenase-2  
 HPV = hypoxic pulmonary vasoconstriction  
 H<sub>2</sub>S = hydrogen sulfide  
 HSD = hypoxic systemic vasodilation  
 iNOS = inducible nitric oxide synthase  
 IPostC = ischemic postconditioning  
 IPreC = ischemic preconditioning  
 K<sub>ATP</sub> = ATP-dependent potassium channels  
 K<sub>Ca</sub> = Ca<sup>2+</sup>-dependent K<sup>+</sup> channels  
 K<sub>v</sub> = voltage-gated potassium channels  
 MAPK = mitogen activated protein kinase  
 MEK-ERK = mitogen-activated protein kinase kinase-extracellular signal-related kinase  
 MPTP = mitochondrial permeability transition pore  
 NADPH = nicotinamide adenine dinucleotide phosphate  
 NEB = neuroepithelial body  
 NEC = neuroepithelial cells  
 NF- $\kappa$ B = nuclear factor- $\kappa$ B  
 NOS = nitric oxide synthase  
 Pao<sub>2</sub> = arterial partial pressure of oxygen  
 PKC = protein kinase C  
 PKG = protein kinase G  
 Po<sub>2</sub> = partial pressure of oxygen  
 PPG = propargyl glycine  
 RI = reperfusion injury  
 RIPreC = remote ischemic preconditioning  
 RISK = reperfusion injury survival kinases  
 ROS = reactive oxygen species  
 RPA = resistance pulmonary arteries  
 SAC = S-allylcysteine  
 SQR = sulfide-quinone oxidoreductase  
 TRP = transient receptor potential

**This article has been cited by:**

1. Yi-Hong Liu , Ming Lu , Li-Fang Hu , Peter T.-H. Wong , George D. Webb , Jin-Song Bian . 2012. Hydrogen Sulfide in the Mammalian Cardiovascular System. *Antioxidants & Redox Signaling* **17**:1, 141-185. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2. Jerzy Be#towski , Anna Jamroz-Wi#niewska . 2012. Modulation of H2S Metabolism by Statins: A New Aspect of Cardiovascular Pharmacology. *Antioxidants & Redox Signaling* **17**:1, 81-94. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
3. Chris Peers , Claudia C. Bauer , John P. Boyle , Jason L. Scragg , Mark L. Dallas . 2012. Modulation of Ion Channels by Hydrogen Sulfide. *Antioxidants & Redox Signaling* **17**:1, 95-105. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
4. Kenneth R. Olson . 2012. A Practical Look at the Chemistry and Biology of Hydrogen Sulfide. *Antioxidants & Redox Signaling* **17**:1, 32-44. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
5. Benjamin Lee Predmore , David Joseph Lefer , Gabriel Gojon . 2012. Hydrogen Sulfide in Biochemistry and Medicine. *Antioxidants & Redox Signaling* **17**:1, 119-140. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
6. Angela Fago, Frank B. Jensen, Bruno Tota, Martin Feelisch, Kenneth R. Olson, Signe Helbo, Sjannie Lefevre, Daniele Mancardi, Anna Palumbo, Guro K. Sandvik, Nini Skovgaard. 2012. Integrating nitric oxide, nitrite and hydrogen sulfide signaling in the physiological adaptations to hypoxia: A comparative approach. *Comparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology* **162**:1, 1-6. [[CrossRef](#)]
7. Dengke K. Ma, Niels Ringstad. 2012. The neurobiology of sensing respiratory gases for the control of animal behavior. *Frontiers in Biology* . [[CrossRef](#)]
8. Kenneth R. Olson, John A. Donald, Ryan A. Dombkowski, Steve F. Perry. 2012. Evolutionary and comparative aspects of nitric oxide, carbon monoxide and hydrogen sulfide. *Respiratory Physiology & Neurobiology* . [[CrossRef](#)]
9. Kenneth R. Olson. 2012. Mitochondrial adaptations to utilize hydrogen sulfide for energy and signaling. *Journal of Comparative Physiology B* . [[CrossRef](#)]
10. Keith J. Buckler. 2012. Effects of exogenous hydrogen sulphide on calcium signalling, background (TASK) K channel activity and mitochondrial function in chemoreceptor cells. *Pflügers Archiv - European Journal of Physiology* . [[CrossRef](#)]
11. Mayumi Kajimura, Tsuyoshi Nakanishi, Toshiki Takenouchi, Takayuki Morikawa, Takako Hishiki, Yoshinori Yukutake, Makoto Suematsu. 2012. Gas biology: Tiny molecules controlling metabolic systems. *Respiratory Physiology & Neurobiology* . [[CrossRef](#)]
12. Julien I. E. Hoffman Basic Anatomy and Physiology of the Heart, and Coronary and Peripheral Circulations 46-70. [[CrossRef](#)]
13. Arvind Sehgal, C. Andrew Ramsden, Patrick J. McNamara. 2012. Indomethacin Impairs Coronary Perfusion in Infants with Hemodynamically Significant Ductus Arteriosus. *Neonatology* **101**:1, 20-27. [[CrossRef](#)]
14. Xiao Yu Tian, Wing Tak Wong, Nazish Sayed, Jialie Luo, Suk Ying Tsang, Zhao Xiang Bian, Ye Lu, Wai San Cheang, Xiaoqiang Yao, Zhen Yu Chen, Yu Huang. 2011. NaHS relaxes rat cerebral artery in vitro via inhibition of l-type voltage-sensitive Ca2+ channel. *Pharmacological Research* . [[CrossRef](#)]
15. Eric R. DeLeon, Gilbrian F. Stoy, Kenneth R. Olson. 2011. Passive loss of hydrogen sulfide in biological experiments. *Analytical Biochemistry* . [[CrossRef](#)]
16. Kenneth R. Olson. 2011. Hydrogen sulfide is an oxygen sensor in the carotid body. *Respiratory Physiology & Neurobiology* . [[CrossRef](#)]
17. Brian P. Dranka, Gloria A. Benavides, Anne R. Diers, Samantha Giordano, Blake R. Zelikson, Colin Reily, Luyun Zou, John C. Chatham, Bradford G. Hill, Jianhua Zhang, Aimee Landar, Victor M. Darley-Usmar. 2011. Assessing bioenergetic function in response to oxidative stress by metabolic profiling. *Free Radical Biology and Medicine* . [[CrossRef](#)]
18. Frédéric Bouillaud , François Blachier . 2011. Mitochondria and Sulfide: A Very Old Story of Poisoning, Feeding, and Signaling?. *Antioxidants & Redox Signaling* **15**:2, 379-391. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
19. Ruma Banerjee . 2011. Hydrogen Sulfide: Redox Metabolism and Signaling. *Antioxidants & Redox Signaling* **15**:2, 339-341. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
20. Kenneth R. Olson. 2011. "Hydrogen sulfide oxidation and the arterial chemoreflex: Effect of methemoglobin" by Haouzi et al. [Respir. Physiol. Neurobiol. (2011)]. *Respiratory Physiology & Neurobiology* . [[CrossRef](#)]

21. Mohammad R. Al-Magableh, Joanne L. Hart. 2011. Mechanism of vasorelaxation and role of endogenous hydrogen sulfide production in mouse aorta. *Naunyn-Schmiedeberg's Archives of Pharmacology* **383**:4, 403-413. [[CrossRef](#)]
22. Katja Wagner, Michael Georgieff, Pierre Asfar, Enrico Calzia, Markus W Knöferl, Peter Radermacher. 2011. Of mice and men (and sheep, swine etc.): The intriguing hemodynamic and metabolic effects of hydrogen sulfide (H<sub>2</sub>S). *Critical Care* **15**:2, 146. [[CrossRef](#)]
23. Peter Oishi, Julien I.E. Hoffman, Bradley P. Fuhrman, Jeffrey R. Fineman. Regional Circulation 217-233. [[CrossRef](#)]
24. Xianfeng Gu, Yi Zhun Zhu. 2011. Therapeutic applications of organosulfur compounds as novel hydrogen sulfide donors and/or mediators. *Expert Review of Clinical Pharmacology* **4**:1, 123-133. [[CrossRef](#)]
25. Yi-Hong Liu, Ming Lu, Jin-Song Bian. 2011. Hydrogen sulfide and renal ischemia. *Expert Review of Clinical Pharmacology* **4**:1, 49-61. [[CrossRef](#)]
26. K. R. Olson, S. F. Perry. 2010. H<sub>2</sub>S and O<sub>2</sub> sensing. *Proceedings of the National Academy of Sciences* **107**:37, E141-E141. [[CrossRef](#)]
27. Rui Wang . 2010. Hydrogen Sulfide: The Third Gasotransmitter in Biology and Medicine. *Antioxidants & Redox Signaling* **12**:9, 1061-1064. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]